Arrowhead Pharmaceuticals, Inc.
NASDAQ Global SelectCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- CEO
- Christopher R. Anzalone
- Full Time Employees
- 609
- Sector
- Healthcare
- Industry
- Biotechnology
- Address
- 177 East Colorado Boulevard Pasadena CA United States of America 91105
- IPO Date
- Dec 16, 1993
- CIK
- 0000879407
- Website
- arrowheadpharma.com
- Similar Companies
- Business
- Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) develops RNA interference (RNAi) therapeutics that silence genes causing intractable diseases using its proprietary Targeted RNAi Molecule (TRiM™) platform; the company's pipeline includes approximately 20 investigational medicines in clinical development across cardiometabolic, pulmonary, liver, neuromuscular, central nervous system, and complement-mediated disease areas, featuring lead candidates such as plozasiran (ARO-APOC3) for severe hypertriglyceridemia and familial chylomicronemia syndrome, zodasiran (ARO-ANG3) for mixed dyslipidemia and homozygous familial hypercholesterolemia, fazirsiran (ARO-AAT) for alpha-1 antitrypsin deficiency-associated liver disease, ARO-C3 for complement-mediated diseases like IgA nephropathy, ARO-MUC5AC and ARO-RAGE for muco-obstructive and inflammatory lung diseases, ARO-HBV for hepatitis B, ARO-DUX4 for facioscapulohumeral muscular dystrophy, ARO-XDH for uncontrolled gout, and others targeting conditions including chronic obstructive pulmonary disease, idiopathic pulmonary fibrosis, and metabolic dysfunction-associated steatohepatitis. Founded in 2003 and headquartered in Pasadena, California, with research and development facilities in Madison and Verona, Wisconsin, and San Diego, California, Arrowhead operates primarily in the United States while advancing partnered and wholly owned programs globally through collaborations with major pharmaceutical companies. Recent developments include a November 2024 global license and collaboration agreement with Sarepta Therapeutics covering multiple clinical and preclinical programs in rare genetic diseases of muscle, CNS, and lungs, providing Arrowhead with $500 million upfront cash, $325 million in equity investment, and potential milestones exceeding $2.7 billion, alongside a $200 million milestone payment from Sarepta in 2025 for progress in the Phase 1/2 study of ARO-DM1 (SRP-1003) for type 1 myotonic dystrophy; the company also maintains ongoing partnerships with GlaxoSmithKline, Takeda, Janssen, Amgen, Horizon Therapeutics, and others, reported FDA approval for its first product plozasiran (branded Redemplo) with a potential commercial launch in 2025 pending final review, and projects cash runway extension into 2028 supported by substantial collaboration revenue of $240.6 million for fiscal year 2024.
Arrowhead Pharmaceuticals to Participate in Upcoming June 2026 Events
Arrowhead Pharmaceuticals to Participate in Upcoming June 2026 Events
Arrowhead Pharmaceuticals Presents New Clinical Data on RNAi-based Obesity and MASH Candidate ARO-INHBE at EASL 2026
Arrowhead Pharmaceuticals Presents New Clinical Data on RNAi-based Obesity and MASH Candidate ARO-INHBE at EASL 2026
Arrowhead Pharmaceuticals Presents New Positive Clinical Cardiometabolic Data at the 94th European Atherosclerosis Society (EAS) Congress
Arrowhead Pharmaceuticals Presents New Positive Clinical Cardiometabolic Data at the 94th European Atherosclerosis Society (EAS) Congress
Arrowhead Pharmaceuticals Eyes Q3 SHASTA Data as REDEMPLO Approvals Build Momentum
Arrowhead Pharmaceuticals, Inc. (ARWR) Presents at Bank of America Global Healthcare Conference 2026 Transcript
Arrowhead Pharmaceuticals Eyes $4B REDEMPLO Opportunity as RNAi Pipeline Readouts Near
Arrowhead Pharmaceuticals: A True Inflection Point Has Arrived
Arrowhead Pharmaceuticals, Inc. (ARWR) Q2 2026 Earnings Call Transcript
Arrowhead Pharmaceuticals Reports Fiscal 2026 Second Quarter Results
Arrowhead Pharmaceuticals Licenses Clinical MASH Program Targeting PNPLA3 to Madrigal Pharmaceuticals
Arrowhead Pharmaceuticals to Participate in Upcoming May 2026 Events
Arrowhead Pharmaceuticals Receives TGA Approval of REDEMPLO® (plozasiran) in Australia, Expanding Global Access for Patients with Familial Chylomicronemia Syndrome (FCS)
B. Metzler seel. Sohn & Co. AG Takes $1.37 Million Position in Arrowhead Pharmaceuticals, Inc. $ARWR
Arrowhead Pharmaceuticals Receives Positive CHMP Opinion Recommending Approval of REDEMPLO® (plozasiran) to Reduce Triglycerides in Adults with Familial Chylomicronemia Syndrome (FCS) in Europe
Farther Finance Advisors LLC Purchases 11,546 Shares of Arrowhead Pharmaceuticals, Inc. $ARWR
Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) Given Consensus Recommendation of “Moderate Buy” by Brokerages
Arrowhead Pharmaceuticals Presents New Long-Term Efficacy and Safety Data for Plozasiran Across a Spectrum of Hypertriglyceridemia at the American College of Cardiology's 75th Annual Scientific Session and Expo